Download PDF
Thromb Haemost 2001; 86(06): 1596-1597
DOI: 10.1055/s-0037-1616778
Letters to the Editor
Schattauer GmbH

Successful Use of Argatroban as an Anticoagulant in Burn-related Severe Acquired Antithrombin III Deficiency after Heparin Failure

Rick Gorman
1   University of Florida, College of Medicine, Shands Hospital, Gainesville, Florida, USA
,
Lucio Gordan
1   University of Florida, College of Medicine, Shands Hospital, Gainesville, Florida, USA
,
Marc Zumberg
1   University of Florida, College of Medicine, Shands Hospital, Gainesville, Florida, USA
,
Craig Kitchens
1   University of Florida, College of Medicine, Shands Hospital, Gainesville, Florida, USA
› Author Affiliations
Further Information

Publication History

Received 18 July 2001

Accepted 02 August 2001

Publication Date:
12 December 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Matsuo T, Masanobu K, Kario K. Development of Argatroban, a direct thrombin inhibitor, and its clinical application. Semin Thromb Hemost 1997; 23 (Suppl. 06) 517-22.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Kowal-Vern A, Gamelli RL, Walenga JM, Hoppenstead D, Sharp-Pucci M, Schumacher HR. The effect of burn wound size on hemostasis: a correlation of the hemostatic changes to the clinical state. J Trauma 1992; 33: 50-7.
    CrossrefPubMedGoogle Scholar
  • 3 Garcia-Avello A, Lorente JA, Cesar-Perez J, Garcia-Frade LJ, Alvarado R, Arevalo JM, Narro JL, Esteban A. Degree of hypercoagulability and hyper-fibrinolysis is related to organ failure and prognosis after burn trauma. Thrombos Res 1998; 89: 59-64.
    CrossrefPubMedGoogle Scholar
  • 4 Kowal-Vern A, McGill V, Walenga JM, Gamelli RL. Antithrombin (H) concentrate infusions are safe and effective in patients with thermal injuries. J Burn Care Rehabil 2000; 21 (Suppl. 02) 115-27.
    CrossrefPubMedGoogle Scholar
  • 5 Kumada T, Abiko Y. Comparative study on heparin and a synthetic thrombin inhibitor No. 805 (MD-805) in experimental antithrombin III-deficient animals. Thrombos Res 1981; 24: 285-98.
    CrossrefPubMedGoogle Scholar
  • 6 Matsuo T, Kario K, Kodama K, Okamoto S. Clinical Application of the synthetic thrombin inhibitor, Argatroban (MD-805). Semin Thromb Hemos 1992; 18 (Suppl. 02) 155-60.
    PubMedGoogle Scholar
  • 7 Kawada T, Kitagawa H, Hoson M, Okada Y, Shiomura J. Clinical application of Argatroban as an alternative anticoagulant for extracorporeal circulation. Hematology-Oncology Clinics of North America 2000; 14 (Suppl. 02) 445-57.
    PubMedGoogle Scholar
  • 8 Kumon K, Tanaka K, Nakajima N, Naito Y. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for the treatment of disseminated intravascular coagulation. Critical Care Medicine 1984; 12: 1039-43.
    CrossrefPubMedGoogle Scholar
  • 9 Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of Argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20 (Suppl. 03) 318-29.
    CrossrefPubMedGoogle Scholar
  • 10 Matsuo T, Yamada T, Nakao K. Effects of a new synthetic anticoagulant (MD805) on platelets. Acta Haematol Jpn 1987; 50: 654-69.
    PubMedGoogle Scholar
  • 11 Leftkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-6.
    CrossrefPubMedGoogle Scholar